MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer CandidateBenzinga • 28 days ago
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data...
Share to Feed
Latest Ratings for MGNX
DateFirmActionFromTo Feb 2022CitigroupUpgradesNeutralBuy Feb 2022SVB LeerinkMaintainsOutperform Feb 2022BMO CapitalInitiates Coverage OnOutperform
View More Analyst...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data...
MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) fell 3.6% on Thursday . The stock traded as low as $14.40 and last traded at $14.42. 30,770 shares traded hands during mid-day trading, a decline of...
Wellington Management Group LLP grew its position in MacroGenics, Inc. (NASDAQ:MGNX Free Report) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund...
This is a signal that MGNX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
This is a signal that MGNX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
This price move could indicate a change in the trend, and may be a sell signal for investors...
This indicator may be signaling that MGNX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...